Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy.

Imiglucerase has been prescribed and found to have an excellent efficacy and safety profile. We report herein the evidence-based data published for 26 years justifying the use of imiglucerase.